BPG is committed to discovery and dissemination of knowledge
Cited by in F6Publishing
For: Hirota S, Ohashi A, Nishida T, Isozaki K, Kinoshita K, Shinomura Y, Kitamura Y. Gain-of-function mutations of platelet-derived growth factor receptor α gene in gastrointestinal stromal tumors. Gastroenterology 2003;125:660-7. [DOI: 10.1016/s0016-5085(03)01046-1] [Cited by in Crossref: 465] [Cited by in F6Publishing: 184] [Article Influence: 24.5] [Reference Citation Analysis]
Number Citing Articles
1 Balachandran VP, Dematteo RP. Targeted therapy for cancer: the gastrointestinal stromal tumor model. Surg Oncol Clin N Am 2013;22:805-21. [PMID: 24012400 DOI: 10.1016/j.soc.2013.06.001] [Cited by in Crossref: 9] [Cited by in F6Publishing: 6] [Article Influence: 1.0] [Reference Citation Analysis]
2 Amato A. Colorectal gastrointestinal stromal tumor. Tech Coloproctol. 2010;14 Suppl 1:S91-S95. [PMID: 20967481 DOI: 10.1007/s10151-010-0631-y] [Cited by in Crossref: 9] [Cited by in F6Publishing: 8] [Article Influence: 0.8] [Reference Citation Analysis]
3 Indio V, Astolfi A, Tarantino G, Urbini M, Patterson J, Nannini M, Saponara M, Gatto L, Santini D, do Valle IF, Castellani G, Remondini D, Fiorentino M, von Mehren M, Brandi G, Biasco G, Heinrich MC, Pantaleo MA. Integrated Molecular Characterization of Gastrointestinal Stromal Tumors (GIST) Harboring the Rare D842V Mutation in PDGFRA Gene. Int J Mol Sci. 2018;19. [PMID: 29510530 DOI: 10.3390/ijms19030732] [Cited by in Crossref: 18] [Cited by in F6Publishing: 13] [Article Influence: 4.5] [Reference Citation Analysis]
4 Klug LR, Corless CL, Heinrich MC. Inhibition of KIT Tyrosine Kinase Activity: Two Decades After the First Approval. J Clin Oncol 2021;39:1674-86. [PMID: 33797935 DOI: 10.1200/JCO.20.03245] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
5 Zhu CZ, Liu D, Kang WM, Yu JC, Ma ZQ, Ye X, Li K. Ghrelin and gastrointestinal stromal tumors. World J Gastroenterol 2017; 23(10): 1758-1763 [PMID: 28348480 DOI: 10.3748/wjg.v23.i10.1758] [Cited by in CrossRef: 10] [Cited by in F6Publishing: 8] [Article Influence: 2.0] [Reference Citation Analysis]
6 Mechtersheimer G, Egerer G, Hensel M, Rieker RJ, Libicher M, Lehnert T, Penzel R. Gastrointestinal stromal tumours and their response to treatment with the tyrosine kinase inhibitor imatinib. Virchows Arch 2004;444:108-18. [PMID: 14735360 DOI: 10.1007/s00428-003-0945-5] [Cited by in Crossref: 17] [Cited by in F6Publishing: 15] [Article Influence: 0.9] [Reference Citation Analysis]
7 Sanders KM, Ward SM, Koh SD. Interstitial cells: regulators of smooth muscle function. Physiol Rev. 2014;94:859-907. [PMID: 24987007 DOI: 10.1152/physrev.00037.2013] [Cited by in Crossref: 242] [Cited by in F6Publishing: 220] [Article Influence: 30.3] [Reference Citation Analysis]
8 Louis AR, Singh S, Gupta SK, Sharma A. Primary GIST of the liver masquerading as primary intra-abdominal tumour: a rare extra-gastrointestinal stromal tumour (EGIST) of the liver. J Gastrointest Cancer. 2014;45:392-394. [PMID: 23749608 DOI: 10.1007/s12029-013-9514-6] [Cited by in Crossref: 10] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
9 Serrano-Candelas E, Ainsua-Enrich E, Navinés-Ferrer A, Rodrigues P, García-Valverde A, Bazzocco S, Macaya I, Arribas J, Serrano C, Sayós J, Arango D, Martin M. Silencing of adaptor protein SH3BP2 reduces KIT/PDGFRA receptors expression and impairs gastrointestinal stromal tumors growth. Mol Oncol 2018;12:1383-97. [PMID: 29885053 DOI: 10.1002/1878-0261.12332] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.0] [Reference Citation Analysis]
10 Javidi-Sharifi N, Traer E, Martinez J, Gupta A, Taguchi T, Dunlap J, Heinrich MC, Corless CL, Rubin BP, Druker BJ, Tyner JW. Crosstalk between KIT and FGFR3 Promotes Gastrointestinal Stromal Tumor Cell Growth and Drug Resistance. Cancer Res. 2015;75:880-891. [PMID: 25432174 DOI: 10.1158/0008-5472.can-14-0573] [Cited by in Crossref: 56] [Cited by in F6Publishing: 34] [Article Influence: 7.0] [Reference Citation Analysis]
11 Zheng S, Huang KE, Tao DY, Pan YL. Gene mutations and prognostic factors analysis in extragastrointestinal stromal tumor of a Chinese three-center study. J Gastrointest Surg. 2011;15:675-681. [PMID: 21274753 DOI: 10.1007/s11605-010-1292-x] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
12 Gupta A, Ma S, Che K, Pobbati AV, Rubin BP. Inhibition of PI3K and MAPK pathways along with KIT inhibitors as a strategy to overcome drug resistance in gastrointestinal stromal tumors. PLoS One 2021;16:e0252689. [PMID: 34324512 DOI: 10.1371/journal.pone.0252689] [Reference Citation Analysis]
13 Mehenni H, Resta N, Park JG, Miyaki M, Guanti G, Costanza MC. Cancer risks in LKB1 germline mutation carriers. Gut. 2006;55:984-990. [PMID: 16407375 DOI: 10.1136/gut.2005.082990] [Cited by in Crossref: 77] [Cited by in F6Publishing: 61] [Article Influence: 4.8] [Reference Citation Analysis]
14 Mitsui Y, Kagemoto K, Itagaki T, Inoue S, Naruse K, Muguruma N, Takayama T. Gastric inflammatory fibroid polyp morphologically changed by Helicobacter pylori eradication. Clin J Gastroenterol 2015;8:77-81. [PMID: 25733031 DOI: 10.1007/s12328-015-0557-z] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.4] [Reference Citation Analysis]
15 Sepe PS, Brugge WR. A guide for the diagnosis and management of gastrointestinal stromal cell tumors. Nat Rev Gastroenterol Hepatol. 2009;6:363-371. [PMID: 19365407 DOI: 10.1038/nrgastro.2009.43] [Cited by in Crossref: 70] [Cited by in F6Publishing: 64] [Article Influence: 5.4] [Reference Citation Analysis]
16 Belinsky MG, Rink L, von Mehren M. Succinate dehydrogenase deficiency in pediatric and adult gastrointestinal stromal tumors. Front Oncol. 2013;3:117. [PMID: 23730622 DOI: 10.3389/fonc.2013.00117] [Cited by in Crossref: 32] [Cited by in F6Publishing: 33] [Article Influence: 3.6] [Reference Citation Analysis]
17 Ma YY, Yu S, He XJ, Xu Y, Wu F, Xia YJ, Guo K, Wang HJ, Ye ZY, Zhang W, Tao HQ. Involvement of c-KIT mutation in the development of gastrointestinal stromal tumors through proliferation promotion and apoptosis inhibition. Onco Targets Ther 2014;7:637-43. [PMID: 24833907 DOI: 10.2147/OTT.S60458] [Cited by in Crossref: 2] [Cited by in F6Publishing: 7] [Article Influence: 0.3] [Reference Citation Analysis]
18 Origone P, Gargiulo S, Mastracci L, Ballestrero A, Battistuzzi L, Casella C, Comandini D, Cusano R, Dei Tos AP, Fiocca R, Garuti A, Ghiorzo P, Martinuzzi C, Toffolatti L, Bianchi Scarrà G; Liguria GIST Unit. Molecular characterization of an Italian series of sporadic GISTs. Gastric Cancer 2013;16:596-601. [PMID: 23291969 DOI: 10.1007/s10120-012-0213-y] [Cited by in Crossref: 16] [Cited by in F6Publishing: 15] [Article Influence: 1.8] [Reference Citation Analysis]
19 Tateishi U, Miyake M, Maeda T, Arai Y, Seki K, Hasegawa T. CT and MRI findings in KIT-weak or KIT-negative atypical gastrointestinal stromal tumors. Eur Radiol. 2006;16:1537-1543. [PMID: 16397744 DOI: 10.1007/s00330-005-0091-3] [Cited by in Crossref: 20] [Cited by in F6Publishing: 16] [Article Influence: 1.3] [Reference Citation Analysis]
20 Nishida T, Tsujimoto M, Takahashi T, Hirota S, Blay JY, Wataya-Kaneda M. Gastrointestinal stromal tumors in Japanese patients with neurofibromatosis type I. J Gastroenterol. 2016;51:571-578. [PMID: 26511941 DOI: 10.1007/s00535-015-1132-6] [Cited by in Crossref: 23] [Cited by in F6Publishing: 22] [Article Influence: 3.3] [Reference Citation Analysis]
21 Suzuki S, Heldin CH, Heuchel RL. Platelet-derived growth factor receptor-beta, carrying the activating mutation D849N, accelerates the establishment of B16 melanoma. BMC Cancer 2007;7:224. [PMID: 18076756 DOI: 10.1186/1471-2407-7-224] [Cited by in Crossref: 13] [Cited by in F6Publishing: 13] [Article Influence: 0.9] [Reference Citation Analysis]
22 Sugiyama Y, Sasaki M, Kouyama M, Tazaki T, Takahashi S, Nakamitsu A. Current treatment strategies and future perspectives for gastrointestinal stromal tumors. World J Gastrointest Pathophysiol 2022; 13(1): 15-33 [DOI: 10.4291/wjgp.v13.i1.15] [Reference Citation Analysis]
23 Dupart J, Zhang W, Trent JC. Gastrointestinal stromal tumor and its targeted therapeutics. Chin J Cancer 2011;30:303-14. [PMID: 21527063 DOI: 10.5732/cjc.011.10062] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
24 Franzini C, Alessandri L, Piscioli I, Donato S, Faraci R, Morelli L, Del Nonno F, Licci S. Extra-gastrointestinal stromal tumor of the greater omentum: report of a case and review of the literature. World J Surg Oncol. 2008;6:25. [PMID: 18294396 DOI: 10.1186/1477-7819-6-25] [Cited by in Crossref: 23] [Cited by in F6Publishing: 24] [Article Influence: 1.6] [Reference Citation Analysis]
25 Agaimy A, Wünsch PH. Sporadic Cajal cell hyperplasia is common in resection specimens for distal oesophageal carcinoma. A retrospective review of 77 consecutive surgical resection specimens. Virchows Arch. 2006;448:288-294. [PMID: 16308708 DOI: 10.1007/s00428-005-0117-x] [Cited by in Crossref: 30] [Cited by in F6Publishing: 26] [Article Influence: 1.8] [Reference Citation Analysis]
26 Carney JA, Stratakis CA. Stromal, fibrous, and fatty gastrointestinal tumors in a patient with a PDGFRA gene mutation. Am J Surg Pathol. 2008;32:1412-1420. [PMID: 18670346 DOI: 10.1097/PAS.0b013e31816250ce] [Cited by in Crossref: 20] [Cited by in F6Publishing: 11] [Article Influence: 1.4] [Reference Citation Analysis]
27 Zong L, Chen P, Jiang J, Wang L, Li QG. Predictive value of p53 expression in the risk of malignant gastrointestinal stromal tumors: Evidence from 19 studies. Exp Ther Med 2012;3:87-92. [PMID: 22969850 DOI: 10.3892/etm.2011.369] [Cited by in Crossref: 3] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
28 Rutkowski P, Debiec-Rychter M, Ruka W. Gastrointestinal stromal tumors: key to diagnosis and choice of therapy. Mol Diagn Ther 2008;12:131-43. [PMID: 18510377 DOI: 10.1007/BF03256278] [Cited by in Crossref: 19] [Cited by in F6Publishing: 10] [Article Influence: 1.4] [Reference Citation Analysis]
29 Tornillo L. Gastrointestinal stromal tumor - an evolving concept. Front Med (Lausanne) 2014;1:43. [PMID: 25593916 DOI: 10.3389/fmed.2014.00043] [Cited by in Crossref: 7] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
30 Bai C, Liu X, Qiu C, Zheng J. FoxM1 is regulated by both HIF-1α and HIF-2α and contributes to gastrointestinal stromal tumor progression. Gastric Cancer 2019;22:91-103. [PMID: 29948390 DOI: 10.1007/s10120-018-0846-6] [Cited by in Crossref: 6] [Cited by in F6Publishing: 5] [Article Influence: 1.5] [Reference Citation Analysis]
31 Okuma Y, Hosomi Y, Watanabe K, Yamada Y, Horio H, Maeda Y, Okamura T, Hishima T. Clinicopathological analysis of thymic malignancies with a consistent retrospective database in a single institution: from Tokyo Metropolitan Cancer Center. BMC Cancer 2014;14:349. [PMID: 24885581 DOI: 10.1186/1471-2407-14-349] [Cited by in Crossref: 15] [Cited by in F6Publishing: 15] [Article Influence: 1.9] [Reference Citation Analysis]
32 Zhou YU, Chen P, Zhong L. Compound gastroenteropancreatic neuroendocrine and gastrointestinal stromal tumors in the stomach: A case report. Oncol Lett 2015;10:2996-8. [PMID: 26722278 DOI: 10.3892/ol.2015.3666] [Reference Citation Analysis]
33 Downs-Kelly E, Rubin BP. Gastrointestinal stromal tumors: molecular mechanisms and targeted therapies. Patholog Res Int 2011;2011:708596. [PMID: 21559207 DOI: 10.4061/2011/708596] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
34 Chan F, Liu Y, Sun H, Li X, Shang H, Fan D, An J, Zhou D. Distribution and possible role of PDGF-AA and PDGFR-alpha in the gastrointestinal tract of adult guinea pigs. Virchows Arch. 2010;457:381-388. [PMID: 20632033 DOI: 10.1007/s00428-010-0946-0] [Cited by in Crossref: 11] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
35 Kocsmár É, Kocsmár I, Szalai L, Lendvai G, Szijártó A, Schaff Z, Kiss A, Kovalszky I, Papp G, Lotz G. Cross-testing of major molecular markers indicates distinct pathways of tumorigenesis in gastric adenocarcinomas and synchronous gastrointestinal stromal tumors. Sci Rep 2020;10:22212. [PMID: 33335133 DOI: 10.1038/s41598-020-78232-2] [Reference Citation Analysis]
36 Wilde BK, Senger JL, Kanthan R. Gastrointestinal schwannoma: an unusual colonic lesion mimicking adenocarcinoma. Can J Gastroenterol 2010;24:233-6. [PMID: 20431810 DOI: 10.1155/2010/943270] [Cited by in Crossref: 12] [Cited by in F6Publishing: 14] [Article Influence: 1.0] [Reference Citation Analysis]
37 Joensuu H. Adjuvant treatment of GIST: patient selection and treatment strategies. Nat Rev Clin Oncol. 2012;9:351-358. [PMID: 22525709 DOI: 10.1038/nrclinonc.2012.74] [Cited by in Crossref: 35] [Cited by in F6Publishing: 35] [Article Influence: 3.5] [Reference Citation Analysis]
38 Pierotti MA, Tamborini E, Negri T, Pricl S, Pilotti S. Targeted therapy in GIST: in silico modeling for prediction of resistance. Nat Rev Clin Oncol 2011;8:161-70. [PMID: 21364689 DOI: 10.1038/nrclinonc.2011.3] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 5.0] [Reference Citation Analysis]
39 Zhang ZC, Fu S, Wang F, Wang HY, Zeng YX, Shao JY. Oncogene mutational profile in nasopharyngeal carcinoma. Onco Targets Ther 2014;7:457-67. [PMID: 24672248 DOI: 10.2147/OTT.S58791] [Cited by in Crossref: 5] [Cited by in F6Publishing: 15] [Article Influence: 0.6] [Reference Citation Analysis]
40 Yamamoto M, Konno H. Current clinical strategy for imatinib-resistant gastrointestinal stromal tumors. Clin J Gastroenterol 2009;2:137-42. [PMID: 26192283 DOI: 10.1007/s12328-009-0077-9] [Reference Citation Analysis]
41 Tarn C, Godwin AK. Molecular research directions in the management of gastrointestinal stromal tumors. Curr Treat Options Oncol. 2005;6:473-486. [PMID: 16242052 DOI: 10.1007/s11864-005-0026-x] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
42 von Mehren M, Heinrich MC, Shi H, Iannazzo S, Mankoski R, Dimitrijević S, Hoehn G, Chiroli S, George S. Clinical efficacy comparison of avapritinib with other tyrosine kinase inhibitors in gastrointestinal stromal tumors with PDGFRA D842V mutation: a retrospective analysis of clinical trial and real-world data. BMC Cancer 2021;21:291. [PMID: 33740926 DOI: 10.1186/s12885-021-08013-1] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
43 Iino S, Horiguchi K, Horiguchi S, Nojyo Y. c-Kit-negative fibroblast-like cells express platelet-derived growth factor receptor alpha in the murine gastrointestinal musculature. Histochem Cell Biol. 2009;131:691-702. [PMID: 19280210 DOI: 10.1007/s00418-009-0580-6] [Cited by in Crossref: 82] [Cited by in F6Publishing: 79] [Article Influence: 6.3] [Reference Citation Analysis]
44 Wu CE, Tzen CY, Wang SY, Yeh CN. Clinical Diagnosis of Gastrointestinal Stromal Tumor (GIST): From the Molecular Genetic Point of View. Cancers (Basel). 2019;11:E679. [PMID: 31100836 DOI: 10.3390/cancers11050679] [Cited by in Crossref: 19] [Cited by in F6Publishing: 19] [Article Influence: 6.3] [Reference Citation Analysis]
45 Zhao Y, Liu X, Xiao K, Wang L, Li Y, Kan M, Jiang Z. Clinicopathological value of long non-coding RNA profiles in gastrointestinal stromal tumor. PeerJ 2021;9:e11946. [PMID: 34557343 DOI: 10.7717/peerj.11946] [Reference Citation Analysis]
46 Engin G, Eraslan S, Kayserili H, Kapran Y, Akman H, Akyuz A, Aykan NF. Imatinib response of gastrointestinal stromal tumor patients with germline mutation on KIT exon 13: A family report. World J Radiol 2017; 9(9): 365-370 [PMID: 29098070 DOI: 10.4329/wjr.v9.i9.365] [Cited by in CrossRef: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.4] [Reference Citation Analysis]
47 Terada T, Maruo H. Esophageal combined carcinomas: Immunohoistochemical and molecular genetic studies. World J Gastroenterol 2012; 18(13): 1545-1551 [PMID: 22509088 DOI: 10.3748/wjg.v18.i13.1545] [Cited by in CrossRef: 9] [Cited by in F6Publishing: 10] [Article Influence: 0.9] [Reference Citation Analysis]
48 Grimminger F, Schermuly RT, Ghofrani HA. Targeting non-malignant disorders with tyrosine kinase inhibitors. Nat Rev Drug Discov 2010;9:956-70. [PMID: 21119733 DOI: 10.1038/nrd3297] [Cited by in Crossref: 96] [Cited by in F6Publishing: 90] [Article Influence: 8.7] [Reference Citation Analysis]
49 Shih AJ, Telesco SE, Radhakrishnan R. Analysis of Somatic Mutations in Cancer: Molecular Mechanisms of Activation in the ErbB Family of Receptor Tyrosine Kinases. Cancers (Basel) 2011;3:1195-231. [PMID: 21701703 DOI: 10.3390/cancers3011195] [Cited by in Crossref: 15] [Cited by in F6Publishing: 14] [Article Influence: 1.7] [Reference Citation Analysis]
50 Altamura G, Corteggio A, Nasir L, Yuan ZQ, Roperto F, Borzacchiello G. Analysis of activated platelet-derived growth factor β receptor and Ras-MAP kinase pathway in equine sarcoid fibroblasts. Biomed Res Int 2013;2013:283985. [PMID: 23936786 DOI: 10.1155/2013/283985] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 0.7] [Reference Citation Analysis]
51 Bai C, Liu X, Zheng JM, Qiu C, Zhu Y, Xu J, Zhao J, Ma D. A novel PDGFRA mutation in gastrointestinal stromal tumours, L839P, is sensitive to imatinib in vitro. Oncol Lett 2012;3:1139-43. [PMID: 22783407 DOI: 10.3892/ol.2012.599] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
52 Nannini M, Tarantino G, Indio V, Ravegnini G, Astolfi A, Urbini M, De Leo A, Santini D, Ceccarelli C, Gruppioni E, Altimari A, Castellucci P, Fanti S, Di Scioscio V, Saponara M, Gatto L, Pession A, Martelli PL, Casadio R, Pantaleo MA. Molecular modelling evaluation of exon 18 His845_Asn848delinsPro PDGFRα mutation in a metastatic GIST patient responding to imatinib. Sci Rep 2019;9:2172. [PMID: 30778083 DOI: 10.1038/s41598-018-38028-x] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
53 Demetri GD, Heinrich MC, Fletcher JA, Fletcher CD, Van den Abbeele AD, Corless CL, Antonescu CR, George S, Morgan JA, Chen MH. Molecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failure. Clin Cancer Res. 2009;15:5902-5909. [PMID: 19737946 DOI: 10.1158/1078-0432.ccr-09-0482] [Cited by in Crossref: 94] [Cited by in F6Publishing: 42] [Article Influence: 7.2] [Reference Citation Analysis]
54 Yegin EG, Duman DG. Small EUS-suspected gastrointestinal stromal tumors of the stomach: An overview for the current state of management. Endosc Ultrasound. 2016;5:69-77. [PMID: 27080604 DOI: 10.4103/2303-9027.180469] [Cited by in Crossref: 16] [Cited by in F6Publishing: 19] [Article Influence: 2.7] [Reference Citation Analysis]
55 Park JW, Cho CH, Jeong DS, Chae HD. Role of F-fluoro-2-deoxyglucose Positron Emission Tomography in Gastric GIST: Predicting Malignant Potential Pre-operatively. J Gastric Cancer. 2011;11:173-179. [PMID: 22076223 DOI: 10.5230/jgc.2011.11.3.173] [Cited by in Crossref: 27] [Cited by in F6Publishing: 26] [Article Influence: 2.5] [Reference Citation Analysis]
56 Balachandran VP, DeMatteo RP. Gastrointestinal stromal tumors: who should get imatinib and for how long? Adv Surg. 2014;48:165-183. [PMID: 25293614 DOI: 10.1016/j.yasu.2014.05.014] [Cited by in Crossref: 20] [Cited by in F6Publishing: 13] [Article Influence: 2.5] [Reference Citation Analysis]
57 Fan J, Yang M, Huang B, Wang Z, Luo D, Zhang J, Zhang P, Shi H, Li Y, Nie X. ALK expressed in a gastrointestinal stromal tumor harboring PDGFRA p. D842V mutation:a case report. Diagn Pathol 2020;15:8. [PMID: 32005261 DOI: 10.1186/s13000-020-0926-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 2.5] [Reference Citation Analysis]
58 Isosaka M, Niinuma T, Nojima M, Kai M, Yamamoto E, Maruyama R, Nobuoka T, Nishida T, Kanda T, Taguchi T, Hasegawa T, Tokino T, Hirata K, Suzuki H, Shinomura Y. A Screen for Epigenetically Silenced microRNA Genes in Gastrointestinal Stromal Tumors. PLoS One 2015;10:e0133754. [PMID: 26214687 DOI: 10.1371/journal.pone.0133754] [Cited by in Crossref: 9] [Cited by in F6Publishing: 12] [Article Influence: 1.3] [Reference Citation Analysis]
59 Liegl-Atzwanger B, Fletcher JA, Fletcher CD. Gastrointestinal stromal tumors. Virchows Arch. 2010;456:111-127. [PMID: 20165865 DOI: 10.1007/s00428-010-0891-y] [Cited by in Crossref: 148] [Cited by in F6Publishing: 131] [Article Influence: 12.3] [Reference Citation Analysis]
60 Joensuu H, Eriksson M, Hall KS, Hartmann JT, Pink D, Schütte J, Ramadori G, Hohenberger P, Duyster J, Al-Batran SE, Schlemmer M, Bauer S, Wardelmann E, Sarlomo-Rikala M, Nilsson B, Sihto H, Ballman KV, Leinonen M, DeMatteo RP, Reichardt P. Risk factors for gastrointestinal stromal tumor recurrence in patients treated with adjuvant imatinib. Cancer 2014;120:2325-33. [PMID: 24737415 DOI: 10.1002/cncr.28669] [Cited by in Crossref: 44] [Cited by in F6Publishing: 36] [Article Influence: 5.5] [Reference Citation Analysis]
61 Baker G, Babb C, Schnugh D, Nayler S, Louw M, Goedhals J, Bringuier PP, Blay JY, Willem P. Molecular characterisation of gastrointestinal stromal tumours in a South African population. Oncol Lett 2013;5:155-60. [PMID: 23255912 DOI: 10.3892/ol.2012.1013] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
62 West RB, Corless CL, Chen X, Rubin BP, Subramanian S, Montgomery K, Zhu S, Ball CA, Nielsen TO, Patel R, Goldblum JR, Brown PO, Heinrich MC, van de Rijn M. The novel marker, DOG1, is expressed ubiquitously in gastrointestinal stromal tumors irrespective of KIT or PDGFRA mutation status. Am J Pathol. 2004;165:107-113. [PMID: 15215166 DOI: 10.1016/s0002-9440(10)63279-8] [Cited by in Crossref: 427] [Cited by in F6Publishing: 196] [Article Influence: 23.7] [Reference Citation Analysis]
63 Jones RL. Practical aspects of risk assessment in gastrointestinal stromal tumors. J Gastrointest Cancer 2014;45:262-7. [PMID: 24802226 DOI: 10.1007/s12029-014-9615-x] [Cited by in Crossref: 16] [Cited by in F6Publishing: 11] [Article Influence: 2.3] [Reference Citation Analysis]
64 Kikuchi A, Monga SP. PDGFRα in liver pathophysiology: emerging roles in development, regeneration, fibrosis, and cancer. Gene Expr 2015;16:109-27. [PMID: 25700367 DOI: 10.3727/105221615X14181438356210] [Cited by in Crossref: 18] [Cited by in F6Publishing: 16] [Article Influence: 2.6] [Reference Citation Analysis]
65 Kim HH. Endoscopic treatment for gastrointestinal stromal tumor: Advantages and hurdles. World J Gastrointest Endosc 2015; 7(3): 192-205 [PMID: 25789089 DOI: 10.4253/wjge.v7.i3.192] [Cited by in CrossRef: 43] [Cited by in F6Publishing: 34] [Article Influence: 6.1] [Reference Citation Analysis]
66 Schildhaus HU, Merkelbach-Bruse S, Büttner R, Wardelmann E. [Pathology and molecular biology of gastrointestinal stromal tumors (GIST)]. Radiologe 2009;49:1104-8. [PMID: 19787330 DOI: 10.1007/s00117-009-1850-y] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
67 Kitamura Y. Gastrointestinal stromal tumors: past, present, and future. J Gastroenterol. 2008;43:499-508. [PMID: 18648736 DOI: 10.1007/s00535-008-2200-y] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.3] [Reference Citation Analysis]
68 Wang YM, Gu ML, Ji F. Succinate dehydrogenase-deficient gastrointestinal stromal tumors. World J Gastroenterol 2015; 21(8): 2303-2314 [PMID: 25741136 DOI: 10.3748/wjg.v21.i8.2303] [Cited by in CrossRef: 29] [Cited by in F6Publishing: 25] [Article Influence: 4.1] [Reference Citation Analysis]
69 Corless CL, McGreevey L, Town A, Schroeder A, Bainbridge T, Harrell P, Fletcher JA, Heinrich MC. KIT gene deletions at the intron 10-exon 11 boundary in GI stromal tumors. J Mol Diagn 2004;6:366-70. [PMID: 15507676 DOI: 10.1016/S1525-1578(10)60533-8] [Cited by in Crossref: 37] [Cited by in F6Publishing: 16] [Article Influence: 2.2] [Reference Citation Analysis]
70 Carvalho I, Milanezi F, Martins A, Reis RM, Schmitt F. Overexpression of platelet-derived growth factor receptor alpha in breast cancer is associated with tumour progression. Breast Cancer Res. 2005;7:R788-R795. [PMID: 16168125 DOI: 10.1186/bcr1304] [Cited by in Crossref: 129] [Cited by in F6Publishing: 122] [Article Influence: 7.6] [Reference Citation Analysis]
71 Zhu H, Zhao S, Jiao R, Zhou J, Zhang C, Miao L. Comparison of endoscopic versus laparoscopic resection for gastric gastrointestinal stromal tumors: A preliminary meta-analysis. J Gastroenterol Hepatol 2020;35:1858-68. [PMID: 32428968 DOI: 10.1111/jgh.15106] [Cited by in Crossref: 4] [Article Influence: 2.0] [Reference Citation Analysis]
72 Somaiah N, von Mehren M. New therapeutic approaches for advanced gastrointestinal stromal tumors. Hematol Oncol Clin North Am 2009;23:139-50, x. [PMID: 19248977 DOI: 10.1016/j.hoc.2008.12.004] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.2] [Reference Citation Analysis]
73 Kim JH, Boo YJ, Jung CW, Park SS, Kim SJ, Mok YJ, Kim SD, Chae YS, Kim CS. Multiple malignant extragastrointestinal stromal tumors of the greater omentum and results of immunohistochemistry and mutation analysis: A case report. World J Gastroenterol 2007; 13(24): 3392-3395 [PMID: 17659683 DOI: 10.3748/wjg.v13.i24.3392] [Cited by in CrossRef: 15] [Cited by in F6Publishing: 17] [Article Influence: 1.0] [Reference Citation Analysis]
74 Patel S. Exploring novel therapeutic targets in GIST: focus on the PI3K/Akt/mTOR pathway. Curr Oncol Rep. 2013;15:386-395. [PMID: 23605780 DOI: 10.1007/s11912-013-0316-6] [Cited by in Crossref: 42] [Cited by in F6Publishing: 41] [Article Influence: 4.7] [Reference Citation Analysis]
75 Nishida T, Takahashi T, Nishitani A, Doi T, Shirao K, Komatsu Y, Nakajima K, Hirota S; Japanese Study Group on GIST. Sunitinib-resistant gastrointestinal stromal tumors harbor cis-mutations in the activation loop of the KIT gene. Int J Clin Oncol 2009;14:143-9. [PMID: 19390946 DOI: 10.1007/s10147-008-0822-y] [Cited by in Crossref: 41] [Cited by in F6Publishing: 37] [Article Influence: 3.2] [Reference Citation Analysis]
76 Bleloch JS, Ballim RD, Kimani S, Parkes J, Panieri E, Willmer T, Prince S. Managing sarcoma: where have we come from and where are we going? Ther Adv Med Oncol 2017;9:637-59. [PMID: 28974986 DOI: 10.1177/1758834017728927] [Cited by in Crossref: 22] [Cited by in F6Publishing: 23] [Article Influence: 4.4] [Reference Citation Analysis]
77 Rock JR, Futtner CR, Harfe BD. The transmembrane protein TMEM16A is required for normal development of the murine trachea. Dev Biol. 2008;321:141-149. [PMID: 15215166 DOI: 10.1016/j.ydbio.2008.06.009] [Cited by in Crossref: 170] [Cited by in F6Publishing: 163] [Article Influence: 9.4] [Reference Citation Analysis]
78 Terada T. Primary extragastrointestinal stromal tumor of the transverse mesocolon without c-kit mutations but with PDGFRA mutations. Med Oncol 2009;26:233-7. [PMID: 18777214 DOI: 10.1007/s12032-008-9092-9] [Cited by in Crossref: 26] [Cited by in F6Publishing: 26] [Article Influence: 1.9] [Reference Citation Analysis]
79 Terada T. Primary multiple extragastrointestinal stromal tumors of the omentum with different mutations of c-kit gene. World J Gastroenterol 2008; 14(47): 7256-7259 [PMID: 19084944 DOI: 10.3748/wjg.14.7256] [Cited by in CrossRef: 32] [Cited by in F6Publishing: 33] [Article Influence: 2.3] [Reference Citation Analysis]
80 Heinrich MC, Owzar K, Corless CL, Hollis D, Borden EC, Fletcher CD, Ryan CW, von Mehren M, Blanke CD, Rankin C. Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group. J Clin Oncol. 2008;26:5360-5367. [PMID: 18955451 DOI: 10.1200/jco.2008.17.4284] [Cited by in Crossref: 416] [Cited by in F6Publishing: 185] [Article Influence: 29.7] [Reference Citation Analysis]
81 Serin KR, Keskin M, Gulluoglu M, Emre A. Atypical localisation of a gastrointestinal stromal tumor: A case report of pancreas gastrointestinal stromal tumor. Ulusal Cer Derg. 2013;29:42-44. [PMID: 25931843 DOI: 10.5152/ucd.2013.11] [Cited by in Crossref: 1] [Cited by in F6Publishing: 7] [Article Influence: 0.1] [Reference Citation Analysis]
82 Kataoka TR, Yamashita N, Furuhata A, Hirata M, Ishida T, Nakamura I, Hirota S, Haga H, Katsuyama E. An inflammatory myofibroblastic tumor exhibiting immunoreactivity to KIT: a case report focusing on a diagnostic pitfall. World J Surg Oncol 2014;12:186. [PMID: 24938355 DOI: 10.1186/1477-7819-12-186] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.3] [Reference Citation Analysis]
83 Theodoropoulos DG. Gastrointestinal tumors of the colon and rectum. Clin Colon Rectal Surg 2011;24:161-70. [PMID: 22942798 DOI: 10.1055/s-0031-1286000] [Cited by in Crossref: 18] [Cited by in F6Publishing: 12] [Article Influence: 1.8] [Reference Citation Analysis]
84 Liu NN, Ohkouchi M, Hashikura Y, Kajimoto N, Matsuda I, Isozaki K, Toh Y, Takahashi T, Nishida T, Hirota S. Extracellular domain c-kit mutation with duplication of Ser501Ala502 found in gastrointestinal stromal tumors is more imatinib- and nilotinib-sensitive than that with duplication of Ala502Tyr503. Lab Invest 2013;93:502-7. [PMID: 23459373 DOI: 10.1038/labinvest.2013.43] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.1] [Reference Citation Analysis]
85 Wang J, Sun P, Chen Y, Yao H, Wang S. Novel 2-phenyloxypyrimidine derivative induces apoptosis and autophagy via inhibiting PI3K pathway and activating MAPK/ERK signaling in hepatocellular carcinoma cells. Sci Rep 2018;8:10923. [PMID: 30026540 DOI: 10.1038/s41598-018-29199-8] [Cited by in Crossref: 9] [Cited by in F6Publishing: 10] [Article Influence: 2.3] [Reference Citation Analysis]
86 Iwamoto R, Kataoka TR, Furuhata A, Ono K, Hirota S, Kawada K, Sakai Y, Haga H. Perivascular epithelioid cell tumor of the descending colon mimicking a gastrointestinal stromal tumor: a case report. World J Surg Oncol 2016;14:285. [PMID: 27842558 DOI: 10.1186/s12957-016-1046-7] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 0.8] [Reference Citation Analysis]
87 Wardelmann E, Büttner R, Merkelbach-Bruse S, Schildhaus HU. Mutation analysis of gastrointestinal stromal tumors: increasing significance for risk assessment and effective targeted therapy. Virchows Arch 2007;451:743-9. [PMID: 17701051 DOI: 10.1007/s00428-007-0473-9] [Cited by in Crossref: 52] [Cited by in F6Publishing: 46] [Article Influence: 3.5] [Reference Citation Analysis]
88 Kikuchi H, Setoguchi T, Miyazaki S, Yamamoto M, Ohta M, Kamiya K, Sakaguchi T, Konno H. Surgical intervention for imatinib and sunitinib-resistant gastrointestinal stromal tumors. Int J Clin Oncol 2011;16:741-5. [PMID: 21394667 DOI: 10.1007/s10147-011-0208-4] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
89 Kuhlgatz J, Sander B, Golas MM, Gunawan B, Schulze T, Schulten HJ, Wardelmann E, Füzesi L. Differential diagnosis of gastrointestinal leiomyoma versus gastrointestinal stromal tumor. Int J Colorectal Dis 2006;21:84-8. [PMID: 15875204 DOI: 10.1007/s00384-004-0730-1] [Cited by in Crossref: 8] [Cited by in F6Publishing: 5] [Article Influence: 0.5] [Reference Citation Analysis]
90 Kurahashi M, Nakano Y, Hennig GW, Ward SM, Sanders KM. Platelet-derived growth factor receptor α-positive cells in the tunica muscularis of human colon. J Cell Mol Med. 2012;16:1397-1404. [PMID: 22225616 DOI: 10.1111/j.1582-4934.2011.01510.x] [Cited by in Crossref: 65] [Cited by in F6Publishing: 59] [Article Influence: 6.5] [Reference Citation Analysis]
91 Lei H, Kazlauskas A. A reactive oxygen species-mediated, self-perpetuating loop persistently activates platelet-derived growth factor receptor α. Mol Cell Biol 2014;34:110-22. [PMID: 24190966 DOI: 10.1128/MCB.00839-13] [Cited by in Crossref: 27] [Cited by in F6Publishing: 13] [Article Influence: 3.0] [Reference Citation Analysis]
92 Nakayama T, Inaba M, Naito S, Mihara Y, Miura S, Taba M, Yoshizaki A, Wen CY, Sekine I. Expression of Angiopoietin-1, 2 and 4 and Tie-1 and 2 in gastrointestinal stromal tumor, leiomyoma and schwannoma. World J Gastroenterol 2007; 13(33): 4473-4479 [PMID: 17724803 DOI: 10.3748/wjg.v13.i33.4473] [Cited by in CrossRef: 3] [Cited by in F6Publishing: 3] [Article Influence: 0.2] [Reference Citation Analysis]
93 Tornillo L, Terracciano LM. An update on molecular genetics of gastrointestinal stromal tumours. J Clin Pathol. 2006;59:557-563. [PMID: 16731599 DOI: 10.1136/jcp.2005.031112] [Cited by in Crossref: 68] [Cited by in F6Publishing: 61] [Article Influence: 4.3] [Reference Citation Analysis]
94 Qiu C, Ma DL. Gastrointestinal stromal tumors: Molecular pathogenesis and targeted therapy. Shijie Huaren Xiaohua Zazhi 2012; 20(18): 1595-1601 [DOI: 10.11569/wcjd.v20.i18.1595] [Reference Citation Analysis]
95 Tan S, Chen P, Ji J, Guo S, Yu D, Asakawa T, Zhou Y, Abe M, Zong L. Genomic Subtypes of GISTs for Stratifying Patient Response to Sunitinib following Imatinib Resistance: A Pooled Analysis and Systematic Review. Dis Markers 2018;2018:1368617. [PMID: 30224936 DOI: 10.1155/2018/1368617] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 0.8] [Reference Citation Analysis]
96 Wetli SC, Leuschner I, Harms D, Rufle A, Foerster A, Bihl M, Graf N, Furtwaengler R, Paulussen M, Briner J, Aslanidis C, Schmitz G, Tornillo L, Mihatsch MJ, Zlobec I, Bruder E. KIT, PDGFRalpha and EGFR analysis in nephroblastoma. Virchows Arch 2008;452:637-50. [PMID: 18478259 DOI: 10.1007/s00428-008-0605-x] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 0.3] [Reference Citation Analysis]
97 Yan W, Zhang A, Powell MJ. Genetic alteration and mutation profiling of circulating cell-free tumor DNA (cfDNA) for diagnosis and targeted therapy of gastrointestinal stromal tumors. Chin J Cancer 2016;35:68. [PMID: 27443349 DOI: 10.1186/s40880-016-0131-1] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.3] [Reference Citation Analysis]
98 Kurokawa Y, Yang HK, Cho H, Ryu MH, Masuzawa T, Park SR, Matsumoto S, Lee HJ, Honda H, Kwon OK, Ishikawa T, Lee KH, Nabeshima K, Kong SH, Shimokawa T, Yook JH, Doki Y, Im SA, Hirota S, Hahn S, Nishida T, Kang YK. Phase II study of neoadjuvant imatinib in large gastrointestinal stromal tumours of the stomach. Br J Cancer 2017;117:25-32. [PMID: 28535156 DOI: 10.1038/bjc.2017.144] [Cited by in Crossref: 33] [Cited by in F6Publishing: 26] [Article Influence: 6.6] [Reference Citation Analysis]
99 Massani M, Capovilla G, Ruffolo C, Bassi N. Gastrointestinal stromal tumour (GIST) presenting as a strangulated inguinal hernia with small bowel obstruction. BMJ Case Rep 2017;2017:bcr2016217273. [PMID: 28104721 DOI: 10.1136/bcr-2016-217273] [Cited by in Crossref: 2] [Cited by in F6Publishing: 3] [Article Influence: 0.4] [Reference Citation Analysis]
100 Zeichner SB, Goldstein DA, Kohn C, Flowers CR. Cost-effectiveness of precision medicine in gastrointestinal stromal tumor and gastric adenocarcinoma. J Gastrointest Oncol 2017;8:513-23. [PMID: 28736638 DOI: 10.21037/jgo.2016.04.03] [Cited by in Crossref: 8] [Cited by in F6Publishing: 8] [Article Influence: 1.6] [Reference Citation Analysis]
101 Salazar M, Barata A, André S, Venâncio J, Francisco I, Cravo M, Nobre-Leitão C. First report of a complete pathological response of a pelvic GIST treated with imatinib as neoadjuvant therapy. Gut 2006;55:585-6. [PMID: 16531543 DOI: 10.1136/gut.2005.086744] [Cited by in Crossref: 27] [Cited by in F6Publishing: 21] [Article Influence: 1.7] [Reference Citation Analysis]
102 Agaimy A, Wünsch PH. Gastrointestinal stromal tumours: a regular origin in the muscularis propria, but an extremely diverse gross presentation. A review of 200 cases to critically re-evaluate the concept of so-called extra-gastrointestinal stromal tumours. Langenbecks Arch Surg. 2006;391:322-329. [PMID: 16402273 DOI: 10.1007/s00423-005-0005-5] [Cited by in Crossref: 76] [Cited by in F6Publishing: 76] [Article Influence: 4.8] [Reference Citation Analysis]
103 Liang JF, Zheng HX, Xiao H, Wu LN, Wang HK. Advances in pathological diagnosis of gastrointestinal stromal tumors. Shijie Huaren Xiaohua Zazhi 2010; 18(1): 58-64 [DOI: 10.11569/wcjd.v18.i1.58] [Cited by in F6Publishing: 2] [Reference Citation Analysis]
104 Ichikawa H, Yoshida A, Kanda T, Kosugi S, Ishikawa T, Hanyu T, Taguchi T, Sakumoto M, Katai H, Kawai A, Wakai T, Kondo T. Prognostic significance of promyelocytic leukemia expression in gastrointestinal stromal tumor; integrated proteomic and transcriptomic analysis. Cancer Sci 2015;106:115-24. [PMID: 25457157 DOI: 10.1111/cas.12565] [Cited by in Crossref: 8] [Cited by in F6Publishing: 7] [Article Influence: 1.0] [Reference Citation Analysis]
105 Gęgotek A, Atalay S, Domingues P, Skrzydlewska E. The Differences in the Proteome Profile of Cannabidiol-Treated Skin Fibroblasts following UVA or UVB Irradiation in 2D and 3D Cell Cultures. Cells 2019;8:E995. [PMID: 31466340 DOI: 10.3390/cells8090995] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 7.0] [Reference Citation Analysis]
106 Ostrowski J, Polkowski M, Paziewska A, Skrzypczak M, Goryca K, Rubel T, Kokoszyñska K, Rutkowski P, Nowecki ZI, Vel Dobosz AJ, Jarosz D, Ruka W, Wyrwicz LS. Functional features of gene expression profiles differentiating gastrointestinal stromal tumours according to KIT mutations and expression. BMC Cancer 2009;9:413. [PMID: 19943934 DOI: 10.1186/1471-2407-9-413] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 1.4] [Reference Citation Analysis]
107 Yuval JB, Khalaileh A, Abu-gazala M, Shachar Y, Keidar A, Mintz Y, Nissan A, Elazary R. The True Incidence of Gastric GIST—a Study Based on Morbidly Obese Patients Undergoing Sleeve Gastrectomy. OBES SURG 2014;24:2134-7. [DOI: 10.1007/s11695-014-1336-5] [Cited by in Crossref: 35] [Cited by in F6Publishing: 31] [Article Influence: 4.4] [Reference Citation Analysis]
108 Bai CG, Hou XW, Wang F, Qiu C, Zhu Y, Huang L, Zhao J, Xu JJ, Ma DL. Stem cell factor-mediated wild-type KIT receptor activation is critical for gastrointestinal stromal tumor cell growth. World J Gastroenterol 2012; 18(23): 2929-2937 [PMID: 22736916 DOI: 10.3748/wjg.v18.i23.2929] [Cited by in CrossRef: 6] [Cited by in F6Publishing: 9] [Article Influence: 0.6] [Reference Citation Analysis]
109 Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8 Suppl 2:S1-41; quiz S42-44. [PMID: 20457867 DOI: 10.6004/jnccn.2010.0116] [Cited by in Crossref: 691] [Cited by in F6Publishing: 549] [Article Influence: 57.6] [Reference Citation Analysis]
110 Schvartsman G, Wagner MJ, Zobniw CM, Trinh VA, Patel S, Somaiah N. An Unusual Case of Central Retinal Vein Occlusion and Review of the Toxicity Profile of Regorafenib in GIST Patients. Curr Oncol Rep 2016;18:49. [PMID: 27319943 DOI: 10.1007/s11912-016-0536-7] [Cited by in Crossref: 3] [Article Influence: 0.5] [Reference Citation Analysis]
111 Eisenberg BL, Trent JC. Adjuvant and neoadjuvant imatinib therapy: current role in the management of gastrointestinal stromal tumors. Int J Cancer. 2011;129:2533-2542. [PMID: 21671474 DOI: 10.1002/ijc.26234] [Cited by in Crossref: 42] [Cited by in F6Publishing: 35] [Article Influence: 3.8] [Reference Citation Analysis]
112 Lamba G, Ambrale S, Lee B, Gupta R, Rafiyath SM, Liu D. Recent advances and novel agents for gastrointestinal stromal tumor (GIST). J Hematol Oncol 2012;5:21. [PMID: 22569033 DOI: 10.1186/1756-8722-5-21] [Cited by in Crossref: 19] [Cited by in F6Publishing: 20] [Article Influence: 1.9] [Reference Citation Analysis]
113 Liu KW, Hu B, Cheng SY. Platelet-derived growth factor signaling in human malignancies. Chin J Cancer 2011;30:581-4. [PMID: 21880178 DOI: 10.5732/cjc.011.10300] [Cited by in Crossref: 7] [Cited by in F6Publishing: 7] [Article Influence: 0.7] [Reference Citation Analysis]
114 Bayraktar UD, Bayraktar S, Rocha-Lima CM. Molecular basis and management of gastrointestinal stromal tumors. World J Gastroenterol 2010; 16(22): 2726-2734 [PMID: 20533592 DOI: 10.3748/wjg.v16.i22.2726] [Cited by in CrossRef: 16] [Cited by in F6Publishing: 18] [Article Influence: 1.3] [Reference Citation Analysis]
115 Stefano S, Giovanni S. The PTEN Tumor Suppressor Gene in Soft Tissue Sarcoma. Cancers (Basel) 2019;11:E1169. [PMID: 31416195 DOI: 10.3390/cancers11081169] [Cited by in Crossref: 4] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
116 Wang L, Yue Y, Yang X, Fan T, Mei B, Hou J, Liang M, Chen G, Wu Z. Platelet Derived Growth Factor Alpha (PDGFRα) Induces the Activation of Cardiac Fibroblasts by Activating c-Kit. Med Sci Monit 2017;23:3808-16. [PMID: 28780584 DOI: 10.12659/msm.906038] [Cited by in Crossref: 6] [Cited by in F6Publishing: 6] [Article Influence: 1.2] [Reference Citation Analysis]
117 Santini MP, Malide D, Hoffman G, Pandey G, D'Escamard V, Nomura-Kitabayashi A, Rovira I, Kataoka H, Ochando J, Harvey RP, Finkel T, Kovacic JC. Tissue-Resident PDGFRα+ Progenitor Cells Contribute to Fibrosis versus Healing in a Context- and Spatiotemporally Dependent Manner. Cell Rep 2020;30:555-570.e7. [PMID: 31940496 DOI: 10.1016/j.celrep.2019.12.045] [Cited by in Crossref: 16] [Cited by in F6Publishing: 16] [Article Influence: 16.0] [Reference Citation Analysis]
118 Indio V, Ravegnini G, Astolfi A, Urbini M, Saponara M, De Leo A, Gruppioni E, Tarantino G, Angelini S, Pession A, Pantaleo MA, Nannini M. Gene Expression Profiling of PDGFRA Mutant GIST Reveals Immune Signatures as a Specific Fingerprint of D842V Exon 18 Mutation. Front Immunol 2020;11:851. [PMID: 32670260 DOI: 10.3389/fimmu.2020.00851] [Cited by in Crossref: 5] [Cited by in F6Publishing: 5] [Article Influence: 2.5] [Reference Citation Analysis]
119 Penzel R, Aulmann S, Moock M, Schwarzbach M, Rieker RJ, Mechtersheimer G. The location of KIT and PDGFRA gene mutations in gastrointestinal stromal tumours is site and phenotype associated. J Clin Pathol 2005;58:634-9. [PMID: 15917417 DOI: 10.1136/jcp.2004.021766] [Cited by in Crossref: 51] [Cited by in F6Publishing: 48] [Article Influence: 3.0] [Reference Citation Analysis]
120 Karanikas M, Machairiotis N, Zarogoulidis P, Stylianaki A, Corcoutsakis N, Mitrakas A, Touzopoulos P, Lyratzopoulos N, Kouklakis G, Spanoudakis M, Polychronidis A. Non-Hodgkin lymphoma and GIST: molecular pathways and clinical expressions. Onco Targets Ther 2012;5:433-8. [PMID: 23251094 DOI: 10.2147/OTT.S38645] [Cited by in F6Publishing: 4] [Reference Citation Analysis]
121 Terada T. Schwannoma and Leiomyoma of the Colon in a Patient with Ulcerative Colitis. J Gastrointest Cancer 2016;47:328-30. [PMID: 26160594 DOI: 10.1007/s12029-015-9747-7] [Cited by in Crossref: 2] [Cited by in F6Publishing: 2] [Article Influence: 0.4] [Reference Citation Analysis]
122 Fujita A, Yamamoto H, Imamura M, Nakamura N, Maehara Y, Tsuneyoshi M, Oda Y. Expression level of the mitotic checkpoint protein and G2-M cell cycle regulators and prognosis in gastrointestinal stromal tumors in the stomach. Virchows Arch 2012;460:163-9. [PMID: 22190007 DOI: 10.1007/s00428-011-1181-z] [Cited by in Crossref: 9] [Cited by in F6Publishing: 9] [Article Influence: 0.8] [Reference Citation Analysis]
123 Dova L, Pentheroudakis G, Golfinopoulos V, Malamou-Mitsi V, Georgiou I, Vartholomatos G, Ntemou A, Fountzilas G, Pavlidis N. Targeting c-KIT, PDGFR in cancer of unknown primary: a screening study for molecular markers of benefit. J Cancer Res Clin Oncol 2008;134:697-704. [PMID: 18064489 DOI: 10.1007/s00432-007-0341-7] [Cited by in Crossref: 14] [Cited by in F6Publishing: 12] [Article Influence: 0.9] [Reference Citation Analysis]
124 Yang Y, Liu X, Ye YF, Wang MC. Diagnostic value of protein kinase C theta for gastrointestinal stromal tumors: a meta-analysis. Shijie Huaren Xiaohua Zazhi 2011; 19(9): 950-955 [DOI: 10.11569/wcjd.v19.i9.950] [Reference Citation Analysis]
125 Ganjoo KN, Patel S. Current and emerging pharmacological treatments for gastrointestinal stromal tumour. Drugs. 2011;71:321-330. [PMID: 21319869 DOI: 10.2165/11585370-000000000-00000] [Cited by in Crossref: 5] [Cited by in F6Publishing: 6] [Article Influence: 0.5] [Reference Citation Analysis]
126 Ip CKM, Ng PKS, Jeong KJ, Shao SH, Ju Z, Leonard PG, Hua X, Vellano CP, Woessner R, Sahni N, Scott KL, Mills GB. Neomorphic PDGFRA extracellular domain driver mutations are resistant to PDGFRA targeted therapies. Nat Commun 2018;9:4583. [PMID: 30389923 DOI: 10.1038/s41467-018-06949-w] [Cited by in Crossref: 20] [Cited by in F6Publishing: 18] [Article Influence: 5.0] [Reference Citation Analysis]
127 Noguchi R, Yano H, Gohda Y, Suda R, Igari T, Ohta Y, Yamashita N, Yamaguchi K, Terakado Y, Ikenoue T, Furukawa Y. Molecular profiles of high-grade and low-grade pseudomyxoma peritonei. Cancer Med 2015;4:1809-16. [PMID: 26475379 DOI: 10.1002/cam4.542] [Cited by in Crossref: 40] [Cited by in F6Publishing: 34] [Article Influence: 5.7] [Reference Citation Analysis]
128 Hou YY, Grabellus F, Weber F, Zhou Y, Tan YS, Li J, Shen KT, Qin J, Sun YH, Qin XY. Impact of KIT and PDGFRA gene mutations on prognosis of patients with gastrointestinal stromal tumors after complete primary tumor resection. J Gastrointest Surg. 2009;13:1583-1592. [PMID: 19291337 DOI: 10.1007/s11605-009-0842-6] [Cited by in Crossref: 26] [Cited by in F6Publishing: 23] [Article Influence: 2.0] [Reference Citation Analysis]
129 Nishida T, Shirao K, Sawaki A, Koseki M, Okamura T, Ohtsu A, Sugiyama T, Miyakawa K, Hirota S. Efficacy and safety profile of imatinib mesylate (ST1571) in Japanese patients with advanced gastrointestinal stromal tumors: a phase II study (STI571B1202). Int J Clin Oncol. 2008;13:244-251. [PMID: 18553235 DOI: 10.1007/s10147-007-0746-y] [Cited by in Crossref: 55] [Cited by in F6Publishing: 46] [Article Influence: 3.9] [Reference Citation Analysis]
130 Tampaki EC, Nakopoulou L, Tampakis A, Kontzoglou K, Weber WP, Kouraklis G. Nestin involvement in tissue injury and cancer--a potential tumor marker? Cell Oncol (Dordr) 2014;37:305-15. [PMID: 25164879 DOI: 10.1007/s13402-014-0193-5] [Cited by in Crossref: 18] [Cited by in F6Publishing: 15] [Article Influence: 2.3] [Reference Citation Analysis]
131 Terada T. Primary small cell carcinoma of the pleura: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes. Med Oncol 2010;27:1119-22. [PMID: 19859843 DOI: 10.1007/s12032-009-9345-2] [Cited by in Crossref: 6] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
132 Kim KM, Kang DW, Moon WS, Park JB, Park CK, Sohn JH, Jeong JS, Cho MY, Jin SY, Choi JS. Gastrointestinal stromal tumors in Koreans: it’s incidence and the clinical, pathologic and immunohistochemical findings. J Korean Med Sci. 2005;20:977-984. [PMID: 16361808 DOI: 10.3346/jkms.2005.20.6.977] [Cited by in Crossref: 65] [Cited by in F6Publishing: 53] [Article Influence: 4.1] [Reference Citation Analysis]
133 Terada T. Primary small cell carcinoma of the mediastinum: a case report with immunohistochemical and molecular genetic analyses of KIT and PDGFRA genes. Med Oncol 2009;26:247-50. [PMID: 18989797 DOI: 10.1007/s12032-008-9116-5] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 1.0] [Reference Citation Analysis]
134 Koyama T, Nimura H, Kobayashi K, Marushima H, Odaira H, Kashimura H, Mitsumori N, Yanaga K. Recurrent gastrointestinal stromal tumor (GIST) of the stomach associated with a novel c-kit mutation after imatinib treatment. Gastric Cancer 2006;9:235-9. [PMID: 16952044 DOI: 10.1007/s10120-006-0368-5] [Cited by in Crossref: 13] [Cited by in F6Publishing: 11] [Article Influence: 0.9] [Reference Citation Analysis]
135 Nishida T, Hirota S, Yanagisawa A, Sugino Y, Minami M, Yamamura Y, Otani Y, Shimada Y, Takahashi F, Kubota T; GIST Guideline Subcommittee. Clinical practice guidelines for gastrointestinal stromal tumor (GIST) in Japan: English version. Int J Clin Oncol. 2008;13:416-430. [PMID: 18946752 DOI: 10.1007/s10147-008-0798-7] [Cited by in Crossref: 191] [Cited by in F6Publishing: 183] [Article Influence: 13.6] [Reference Citation Analysis]
136 Gao X, Ma C, Sun X, Zhao Q, Fang Y, Jiang Y, Shen K, Shen X. Upregulation of ZNF148 in SDHB-deficient gastrointestinal stromal tumor potentiates Forkhead box M1-mediated transcription and promotes tumor cell invasion. Cancer Sci 2020;111:1266-78. [PMID: 32060966 DOI: 10.1111/cas.14348] [Cited by in F6Publishing: 1] [Reference Citation Analysis]
137 Atay S, Wilkey DW, Milhem M, Merchant M, Godwin AK. Insights into the Proteome of Gastrointestinal Stromal Tumors-Derived Exosomes Reveals New Potential Diagnostic Biomarkers. Mol Cell Proteomics 2018;17:495-515. [PMID: 29242380 DOI: 10.1074/mcp.RA117.000267] [Cited by in Crossref: 26] [Cited by in F6Publishing: 15] [Article Influence: 5.2] [Reference Citation Analysis]
138 Chen P, Zong L, Zhao W, Shi L. Efficacy evaluation of imatinib treatment in patients with gastrointestinal stromal tumors: A meta-analysis. World J Gastroenterol 2010; 16(33): 4227-4232 [PMID: 20806443 DOI: 10.3748/wjg.v16.i33.4227] [Cited by in CrossRef: 12] [Cited by in F6Publishing: 15] [Article Influence: 1.0] [Reference Citation Analysis]
139 Demetri GD, von Mehren M, Antonescu CR, DeMatteo RP, Ganjoo KN, Maki RG, Pisters PW, Raut CP, Riedel RF, Schuetze S, Sundar HM, Trent JC, Wayne JD. NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors. J Natl Compr Canc Netw. 2010;8 Suppl 2:S1-S41; quiz S42-S44. [PMID: 20457867 DOI: 10.1002/jso.21485] [Cited by in Crossref: 17] [Cited by in F6Publishing: 17] [Article Influence: 1.4] [Reference Citation Analysis]
140 Yayu H, Changmao Z, Yijun D, Na L, Tianwen X, Yangbin D. Recurrent and metastatic extragastrointestinal stromal tumors of the mesentery with C-KIT and PDGFRA mutations: a case report. Cancer Biol Ther 2020;21:101-7. [PMID: 31599195 DOI: 10.1080/15384047.2019.1671110] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 0.3] [Reference Citation Analysis]
141 Hong CS, Partovi E, Clune J, Huttner A, Park HS, Omay SB. Genomic Characterization of Radiation-Induced Intracranial Undifferentiated Pleomorphic Sarcoma. Case Rep Genet 2021;2021:5586072. [PMID: 33747576 DOI: 10.1155/2021/5586072] [Reference Citation Analysis]
142 Takahashi T, Elzawahry A, Mimaki S, Furukawa E, Nakatsuka R, Nakamura H, Nishigaki T, Serada S, Naka T, Hirota S, Shibata T, Tsuchihara K, Nishida T, Kato M. Genomic and transcriptomic analysis of imatinib resistance in gastrointestinal stromal tumors. Genes Chromosomes Cancer 2017;56:303-13. [PMID: 27997714 DOI: 10.1002/gcc.22438] [Cited by in Crossref: 14] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
143 Casella C, Villanacci V, D'Adda F, Codazzi M, Salerni B. Primary Extra-gastrointestinal Stromal Tumor of Retroperitoneum. Clin Med Insights Oncol 2012;6:189-97. [PMID: 22563251 DOI: 10.4137/CMO.S9180] [Cited by in Crossref: 12] [Cited by in F6Publishing: 9] [Article Influence: 1.2] [Reference Citation Analysis]
144 Ramos AH, Dutt A, Mermel C, Perner S, Cho J, Lafargue CJ, Johnson LA, Stiedl AC, Tanaka KE, Bass AJ, Barretina J, Weir BA, Beroukhim R, Thomas RK, Minna JD, Chirieac LR, Lindeman NI, Giordano T, Beer DG, Wagner P, Wistuba II, Rubin MA, Meyerson M. Amplification of chromosomal segment 4q12 in non-small cell lung cancer. Cancer Biol Ther 2009;8:2042-50. [PMID: 19755855 DOI: 10.4161/cbt.8.21.9764] [Cited by in Crossref: 62] [Cited by in F6Publishing: 58] [Article Influence: 4.8] [Reference Citation Analysis]
145 Coffey RJ, Washington MK, Corless CL, Heinrich MC. Ménétrier disease and gastrointestinal stromal tumors: hyperproliferative disorders of the stomach. J Clin Invest. 2007;117:70-80. [PMID: 17200708 DOI: 10.1172/jci30491] [Cited by in Crossref: 81] [Cited by in F6Publishing: 34] [Article Influence: 5.4] [Reference Citation Analysis]
146 Jakhetiya A, Garg PK, Prakash G, Sharma J, Pandey R, Pandey D. Targeted therapy of gastrointestinal stromal tumours. World J Gastrointest Surg 2016; 8(5): 345-352 [PMID: 27231512 DOI: 10.4240/wjgs.v8.i5.345] [Cited by in CrossRef: 20] [Cited by in F6Publishing: 16] [Article Influence: 3.3] [Reference Citation Analysis]
147 Zamò A, Bertolaso A, Franceschetti I, Weirich G, Capelli P, Pecori S, Chilosi M, Hoefler H, Menestrina F, Scarpa A. Microfluidic deletion/insertion analysis for rapid screening of KIT and PDGFRA mutations in CD117-positive gastrointestinal stromal tumors: diagnostic applications and report of a new KIT mutation. J Mol Diagn 2007;9:151-7. [PMID: 17384206 DOI: 10.2353/jmoldx.2007.060041] [Cited by in Crossref: 12] [Cited by in F6Publishing: 12] [Article Influence: 0.8] [Reference Citation Analysis]
148 Nakayama T, Cho YC, Mine Y, Yoshizaki A, Naito S, Wen CY, Sekine I. Expression of vascular endothelial growth factor and its receptors VEGFR-1 and 2 in gastrointestinal stromal tumors, leiomyomas and schwannomas. World J Gastroenterol 2006; 12(38): 6182-6187 [PMID: 17036392 DOI: 10.3748/wjg.v12.i38.6182] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 14] [Article Influence: 1.1] [Reference Citation Analysis]
149 Tu H, Li Q, Cai J, Chen Z, Yang H, Jiang H, Mao Y, Shou Z, Chen J. Extragastrointestinal stromal tumor in a kidney transplant recipient. Clin Exp Nephrol 2012;16:350-3. [PMID: 22009637 DOI: 10.1007/s10157-011-0550-x] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 0.5] [Reference Citation Analysis]
150 Takahashi Y, Suzuki M, Fukusato T. Plexiform angiomyxoid myofibroblastic tumor of the stomach. World J Gastroenterol 2010; 16(23): 2835-2840 [PMID: 20556828 DOI: 10.3748/wjg.v16.i23.2835] [Cited by in CrossRef: 41] [Cited by in F6Publishing: 38] [Article Influence: 3.4] [Reference Citation Analysis]
151 Kikuchi H, Hiramatsu Y, Kamiya K, Morita Y, Sakaguchi T, Konno H, Takeuchi H. Surgery for metastatic gastrointestinal stromal tumor: to whom and how to? Transl Gastroenterol Hepatol 2018;3:14. [PMID: 29682621 DOI: 10.21037/tgh.2018.02.02] [Cited by in Crossref: 5] [Cited by in F6Publishing: 3] [Article Influence: 1.3] [Reference Citation Analysis]
152 Miwa S, Nakajima T, Murai Y, Takano Y, Sugiyama T. Mutation assay of the novel gene DOG1 in gastrointestinal stromal tumors (GISTs). J Gastroenterol. 2008;43:531-537. [PMID: 18648740 DOI: 10.1007/s00535-008-2195-4] [Cited by in Crossref: 21] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
153 Wei T, Zhang LN, Lv Y, Ma XY, Zhi L, Liu C, Ma F, Zhang XF. Overexpression of platelet-derived growth factor receptor alpha promotes tumor progression and indicates poor prognosis in hepatocellular carcinoma. Oncotarget. 2014;5:10307-10317. [PMID: 25333264 DOI: 10.18632/oncotarget.2537] [Cited by in Crossref: 35] [Cited by in F6Publishing: 32] [Article Influence: 5.0] [Reference Citation Analysis]
154 Chen HW, Chen TW. Genomic-guided precision therapy for soft tissue sarcoma. ESMO Open 2020;5:e000626. [PMID: 32132106 DOI: 10.1136/esmoopen-2019-000626] [Cited by in Crossref: 3] [Cited by in F6Publishing: 1] [Article Influence: 3.0] [Reference Citation Analysis]
155 Murayama Y, Yamamoto M, Iwasaki R, Miyazaki T, Saji Y, Doi Y, Fukuda H, Hirota S, Hiratsuka M. Greater omentum gastrointestinal stromal tumor with PDGFRA-mutation and hemoperitoneum. World J Gastrointest Oncol 2012; 4(5): 119-124 [PMID: 22645636 DOI: 10.4251/wjgo.v4.i5.119] [Cited by in CrossRef: 8] [Cited by in F6Publishing: 7] [Article Influence: 0.8] [Reference Citation Analysis]
156 Terada T. Histopathological study using computer database of 10 000 consecutive gastric specimens: (2) malignant lesions. Gastroenterol Rep (Oxf) 2016;4:54-8. [PMID: 25667235 DOI: 10.1093/gastro/gou094] [Cited by in F6Publishing: 3] [Reference Citation Analysis]
157 Poveda A, del Muro XG, López-Guerrero JA, Martínez V, Romero I, Valverde C, Cubedo R, Martín-Broto J. GEIS 2013 guidelines for gastrointestinal sarcomas (GIST). Cancer Chemother Pharmacol. 2014;74:883-898. [PMID: 25193432 DOI: 10.1007/s00280-014-2547-0] [Cited by in Crossref: 33] [Cited by in F6Publishing: 24] [Article Influence: 4.1] [Reference Citation Analysis]
158 Rossi ED, Martini M, Bizzarro T, Schmitt F, Longatto-Filho A, Larocca LM. Somatic mutations in solid tumors: a spectrum at the service of diagnostic armamentarium or an indecipherable puzzle? The morphological eyes looking for BRAF and somatic molecular detections on cyto-histological samples. Oncotarget 2017;8:3746-60. [PMID: 27738305 DOI: 10.18632/oncotarget.12564] [Cited by in Crossref: 5] [Cited by in F6Publishing: 4] [Article Influence: 1.3] [Reference Citation Analysis]
159 Bakoyiannis A, Delis S, Triantopoulou C, Dervenis C. Rare cystic liver lesions: A diagnostic and managing challenge. World J Gastroenterol 2013; 19(43): 7603-7619 [PMID: 24282350 DOI: 10.3748/wjg.v19.i43.7603] [Cited by in CrossRef: 26] [Cited by in F6Publishing: 15] [Article Influence: 2.9] [Reference Citation Analysis]
160 Kameyama H, Kanda T, Tajima Y, Shimada Y, Ichikawa H, Hanyu T, Ishikawa T, Wakai T. Management of rectal gastrointestinal stromal tumor. Transl Gastroenterol Hepatol 2018;3:8. [PMID: 29552659 DOI: 10.21037/tgh.2018.01.08] [Cited by in Crossref: 11] [Cited by in F6Publishing: 13] [Article Influence: 2.8] [Reference Citation Analysis]
161 Conte GA, Harmon JS, Masia RA, Marchesani D, Sun X, Pichardo EM, Parrilla FB, Levitt MJ, Chinnici AA. Small Bowel Gastrointestinal Stromal Tumor as a Gateway for Streptococcus anginosus Causing Multiple Liver Abscesses. World J Oncol 2020;11:116-21. [PMID: 32494319 DOI: 10.14740/wjon1270] [Reference Citation Analysis]
162 Yamamoto H, Tobo T, Nakamori M, Imamura M, Kojima A, Oda Y, Nakamura N, Takahira T, Yao T, Tsuneyoshi M. Neurofibromatosis type 1-related gastrointestinal stromal tumors: a special reference to loss of heterozygosity at 14q and 22q. J Cancer Res Clin Oncol. 2009;135:791-798. [PMID: 19020900 DOI: 10.1007/s00432-008-0514-z] [Cited by in Crossref: 31] [Cited by in F6Publishing: 26] [Article Influence: 2.2] [Reference Citation Analysis]
163 Nishida T, Sakai Y, Takagi M, Ozaka M, Kitagawa Y, Kurokawa Y, Masuzawa T, Naito Y, Kagimura T, Hirota S; members of the STAR ReGISTry Study Group. Adherence to the guidelines and the pathological diagnosis of high-risk gastrointestinal stromal tumors in the real world. Gastric Cancer 2020;23:118-25. [PMID: 31041650 DOI: 10.1007/s10120-019-00966-4] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.0] [Reference Citation Analysis]
164 Mei L, Du W, Idowu M, von Mehren M, Boikos SA. Advances and Challenges on Management of Gastrointestinal Stromal Tumors. Front Oncol. 2018;8:135. [PMID: 29868467 DOI: 10.3389/fonc.2018.00135] [Cited by in Crossref: 23] [Cited by in F6Publishing: 21] [Article Influence: 5.8] [Reference Citation Analysis]
165 Din OS, Woll PJ. Treatment of gastrointestinal stromal tumor: focus on imatinib mesylate. Ther Clin Risk Manag 2008;4:149-62. [PMID: 18728705 DOI: 10.2147/tcrm.s1526] [Cited by in Crossref: 28] [Cited by in F6Publishing: 16] [Article Influence: 2.5] [Reference Citation Analysis]
166 Zhao X, Yue C. Gastrointestinal stromal tumor. J Gastrointest Oncol 2012;3:189-208. [PMID: 22943011 DOI: 10.3978/j.issn.2078-6891.2012.031] [Cited by in F6Publishing: 41] [Reference Citation Analysis]
167 Chew HY, Chan V, Simpson F, Dolcetti R. Will Next-Generation Immunotherapy Overcome the Intrinsic Diversity and Low Immunogenicity of Sarcomas to Improve Clinical Benefit? Cancers (Basel) 2020;12:E3392. [PMID: 33207697 DOI: 10.3390/cancers12113392] [Cited by in Crossref: 3] [Cited by in F6Publishing: 2] [Article Influence: 1.5] [Reference Citation Analysis]
168 Shinomura Y, Kinoshita K, Tsutsui S, Hirota S. Pathophysiology, diagnosis, and treatment of gastrointestinal stromal tumors. J Gastroenterol. 2005;40:775-780. [PMID: 16143881 DOI: 10.1007/s00535-005-1674-0] [Cited by in Crossref: 65] [Cited by in F6Publishing: 52] [Article Influence: 3.8] [Reference Citation Analysis]
169 Zong L, Chen P. Prognostic value of KIT/PDGFRA mutations in gastrointestinal stromal tumors: a meta-analysis. World J Surg Oncol 2014;12:71. [PMID: 24674052 DOI: 10.1186/1477-7819-12-71] [Cited by in Crossref: 5] [Cited by in F6Publishing: 7] [Article Influence: 0.6] [Reference Citation Analysis]
170 Andrae J, Gallini R, Betsholtz C. Role of platelet-derived growth factors in physiology and medicine. Genes Dev 2008;22:1276-312. [PMID: 18483217 DOI: 10.1101/gad.1653708] [Cited by in Crossref: 1401] [Cited by in F6Publishing: 1304] [Article Influence: 100.1] [Reference Citation Analysis]
171 Lopes LF, Bacchi CE. Imatinib treatment for gastrointestinal stromal tumour (GIST). J Cell Mol Med 2010;14:42-50. [PMID: 19968734 DOI: 10.1111/j.1582-4934.2009.00983.x] [Cited by in Crossref: 25] [Cited by in F6Publishing: 27] [Article Influence: 1.9] [Reference Citation Analysis]
172 Takahashi T, Nakajima K, Nishitani A, Souma Y, Hirota S, Sawa Y, Nishida T. An enhanced risk-group stratification system for more practical prognostication of clinically malignant gastrointestinal stromal tumors. Int J Clin Oncol. 2007;12:369-374. [PMID: 17929119 DOI: 10.1007/s10147-007-0705-7] [Cited by in Crossref: 73] [Cited by in F6Publishing: 54] [Article Influence: 4.9] [Reference Citation Analysis]
173 Terada T. Amelanotic malignant melanoma of the esophagus: Report of two cases with immunohistochemical and molecular genetic study of KIT and PDGFRAWorld J Gastroenterol 2009; 15(21): 2679-2683 [PMID: 19496203 DOI: 10.3748/wjg.15.2679] [Cited by in CrossRef: 17] [Cited by in F6Publishing: 13] [Article Influence: 1.3] [Reference Citation Analysis]
174 Hedenström P, Andersson C, Sjövall H, Enlund F, Nilsson O, Nilsson B, Sadik R. Pretreatment Tumor DNA Sequencing of KIT and PDGFRA in Endosonography-Guided Biopsies Optimizes the Preoperative Management of Gastrointestinal Stromal Tumors. Mol Diagn Ther 2020;24:201-14. [PMID: 32124386 DOI: 10.1007/s40291-020-00451-0] [Cited by in Crossref: 1] [Article Influence: 1.0] [Reference Citation Analysis]
175 Olson LE, Soriano P. Increased PDGFRalpha activation disrupts connective tissue development and drives systemic fibrosis. Dev Cell. 2009;16:303-313. [PMID: 19217431 DOI: 10.1016/j.devcel.2008.12.003] [Cited by in Crossref: 174] [Cited by in F6Publishing: 167] [Article Influence: 13.4] [Reference Citation Analysis]
176 Moenning A, Jäger R, Egert A, Kress W, Wardelmann E, Schorle H. Sustained platelet-derived growth factor receptor alpha signaling in osteoblasts results in craniosynostosis by overactivating the phospholipase C-gamma pathway. Mol Cell Biol 2009;29:881-91. [PMID: 19047372 DOI: 10.1128/MCB.00885-08] [Cited by in Crossref: 31] [Cited by in F6Publishing: 19] [Article Influence: 2.2] [Reference Citation Analysis]
177 Wardelmann E, Hrychyk A, Merkelbach-Bruse S, Pauls K, Goldstein J, Hohenberger P, Losen I, Manegold C, Büttner R, Pietsch T. Association of platelet-derived growth factor receptor alpha mutations with gastric primary site and epithelioid or mixed cell morphology in gastrointestinal stromal tumors. J Mol Diagn. 2004;6:197-204. [PMID: 15269295 DOI: 10.1016/S1525-1578(10)60510-7] [Cited by in Crossref: 121] [Cited by in F6Publishing: 35] [Article Influence: 7.1] [Reference Citation Analysis]
178 Yamaguchi U, Hasegawa T, Masuda T, Sekine S, Kawai A, Chuman H, Shimoda T. Differential diagnosis of gastrointestinal stromal tumor and other spindle cell tumors in the gastrointestinal tract based on immunohistochemical analysis. Virchows Arch. 2004;445:142-150. [PMID: 15232741 DOI: 10.1007/s00428-004-1055-8] [Cited by in Crossref: 50] [Cited by in F6Publishing: 42] [Article Influence: 2.8] [Reference Citation Analysis]
179 Todoroki T, Sano T, Sakurai S, Segawa A, Saitoh T, Fujikawa K, Yamada S, Hirahara N, Tsushima Y, Motojima R. Primary omental gastrointestinal stromal tumor (GIST). World J Surg Oncol. 2007;5:66. [PMID: 17565683 DOI: 10.1186/1477-7819-5-66] [Cited by in Crossref: 22] [Cited by in F6Publishing: 21] [Article Influence: 1.5] [Reference Citation Analysis]
180 Choi H. Critical issues in response evaluation on computed tomography: lessons from the gastrointestinal stromal tumor model. Curr Oncol Rep. 2005;7:307-311. [PMID: 15946591 DOI: 10.1007/s11912-005-0055-4] [Cited by in Crossref: 79] [Cited by in F6Publishing: 68] [Article Influence: 4.6] [Reference Citation Analysis]
181 Steeghs EMP, Gelderblom H, Ho VKY, Voorham QJM, Willems SM, Grünberg K, Ligtenberg MJL; PATH consortium. Nationwide evaluation of mutation-tailored treatment of gastrointestinal stromal tumors in daily clinical practice. Gastric Cancer 2021;24:990-1002. [PMID: 33909171 DOI: 10.1007/s10120-021-01190-9] [Cited by in Crossref: 1] [Cited by in F6Publishing: 1] [Article Influence: 1.0] [Reference Citation Analysis]
182 Machairas A, Karamitopoulou E, Tsapralis D, Karatzas T, Machairas N, Misiakos EP. Gastrointestinal stromal tumors (GISTs): an updated experience. Dig Dis Sci. 2010;55:3315-3327. [PMID: 20725786 DOI: 10.1007/s10620-010-1360-9] [Cited by in Crossref: 16] [Cited by in F6Publishing: 10] [Article Influence: 1.3] [Reference Citation Analysis]
183 Isozaki K, Hirota S. Gain-of-Function Mutations of Receptor Tyrosine Kinases in Gastrointestinal Stromal Tumors. Curr Genomics 2006;7:469-75. [PMID: 18369405 DOI: 10.2174/138920206779315755] [Cited by in Crossref: 32] [Cited by in F6Publishing: 31] [Article Influence: 2.9] [Reference Citation Analysis]
184 Wong RJ, Longacre TA, Poultsides G, Park W, Rothenberg ME. Gastrointestinal stromal tumor: an unusual cause of gastrointestinal bleeding. Dig Dis Sci 2013;58:3112-6. [PMID: 23633157 DOI: 10.1007/s10620-013-2678-x] [Cited by in Crossref: 2] [Cited by in F6Publishing: 1] [Article Influence: 0.2] [Reference Citation Analysis]
185 Kono M, Tsuji N, Ozaki N, Matsumoto N, Takaba T, Okumura N, Kawasaki M, Tomita T, Umehara Y, Taniike S, Hatabe S, Funai S, Ono Y, Ochiai K, Maekura S, Kudo M. Primary leiomyosarcoma of the colon. Clin J Gastroenterol 2015;8:217-22. [PMID: 26208828 DOI: 10.1007/s12328-015-0584-9] [Cited by in Crossref: 11] [Cited by in F6Publishing: 9] [Article Influence: 1.6] [Reference Citation Analysis]
186 Yamaoka T, Kusumoto S, Ando K, Ohba M, Ohmori T. Receptor Tyrosine Kinase-Targeted Cancer Therapy. Int J Mol Sci 2018;19:E3491. [PMID: 30404198 DOI: 10.3390/ijms19113491] [Cited by in Crossref: 75] [Cited by in F6Publishing: 66] [Article Influence: 18.8] [Reference Citation Analysis]
187 Waidhauser J, Bornemann A, Trepel M, Märkl B. Frequency, localization, and types of gastrointestinal stromal tumor-associated neoplasia. World J Gastroenterol 2019; 25(30): 4261-4277 [PMID: 31435178 DOI: 10.3748/wjg.v25.i30.4261] [Cited by in CrossRef: 7] [Cited by in F6Publishing: 5] [Article Influence: 2.3] [Reference Citation Analysis]
188 Van den Abbeele AD, Gatsonis C, de Vries DJ, Melenevsky Y, Szot-Barnes A, Yap JT, Godwin AK, Rink L, Huang M, Blevins M, Sicks J, Eisenberg B, Siegel BA. ACRIN 6665/RTOG 0132 phase II trial of neoadjuvant imatinib mesylate for operable malignant gastrointestinal stromal tumor: monitoring with 18F-FDG PET and correlation with genotype and GLUT4 expression. J Nucl Med 2012;53:567-74. [PMID: 22381410 DOI: 10.2967/jnumed.111.094425] [Cited by in Crossref: 38] [Cited by in F6Publishing: 30] [Article Influence: 3.8] [Reference Citation Analysis]
189 Gheorghe G, Bacalbasa N, Ceobanu G, Ilie M, Enache V, Constantinescu G, Bungau S, Diaconu CC. Gastrointestinal Stromal Tumors-A Mini Review. J Pers Med 2021;11:694. [PMID: 34442339 DOI: 10.3390/jpm11080694] [Reference Citation Analysis]
190 Corless CL, Barnett CM, Heinrich MC. Gastrointestinal stromal tumours: origin and molecular oncology. Nat Rev Cancer 2011;11:865-78. [DOI: 10.1038/nrc3143] [Cited by in Crossref: 461] [Cited by in F6Publishing: 413] [Article Influence: 41.9] [Reference Citation Analysis]
191 Zhu JQ, Ou WB. Therapeutic targets in gastrointestinal stromal tumors. World J Transl Med 2015; 4(1): 25-37 [DOI: 10.5528/wjtm.v4.i1.25] [Cited by in CrossRef: 1] [Article Influence: 0.1] [Reference Citation Analysis]